The British Society for Haematology has published updated guidelines for the diagnosis and management of chronic myeloid leukemia in adults and children.
Patients with relapsed/refractory AML who do not respond to venetoclax-based salvage therapy may have a response to intensified chemotherapy.
CP-CML patients who remain on first-line TKI therapy have better clinical responses than patients who switch within the first 3 years.
Fixed-duration venetoclax plus rituximab provides sustained, durable response for patients with relapsed chronic lymphocytic leukemia.
Most patients with CML are being prescribed costly second-generation TKIs, even though generic imatinib has been available since 2016.
Risk factors include male sex, older age at diagnosis, White race.
Venetoclax plus obinutuzumab appears to yield good responses for a limited duration among patients with previously untreated CLL.
Recent guidelines have provided additional information on the treatment, management, and risk-stratifications of acute myeloid leukemia in older patients.
Sorafenib maintenance showed positive relapse, survival, and safety outcomes for patients with FLT3-ITD acute myeloid leukemia after transplantation.
The nongovernmental organizations argued that patents for this CAR-T should never have been granted in the first place because the underlying technology is not novel.
